LOS ANGELES--(BUSINESS WIRE)---- $MRX--MRX Investors Have Opportunity to Lead Marex Group plc Securities Fraud Lawsuit with the Schall Law Firm. ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who sold short Marex Group PLC securities, alleging that the company misled investors regarding its financial performance and revenue projections [1][2]. Group 1: Allegations Against Marex Group PLC - The lawsuit claims that Marex Group PLC improperly inflated its cash flow, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions [2]. - As a result of these alleged misrepresentations, class members have reportedly suffered significant losses and damages [2]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by December 8, 2025, to represent the class in the litigation [3]. - Investors do not need to participate actively in the case to be eligible for any potential recovery, and they can remain absent class members if they choose [3]. Group 3: Robbins LLP Overview - Robbins LLP is recognized for its leadership in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4].

Core Viewpoint - A class action lawsuit has been filed against Marex Group plc for alleged securities fraud, with claims of significant accounting irregularities and misleading disclosures impacting investors [1][5]. Group 1: Allegations and Findings - A report by NINGI Research on August 5, 2025, accused Marex of engaging in a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions to conceal losses and inflate profits [3]. - The report highlighted discrepancies, including a $17 million receivable created without basis, a subsidiary's profit inflated by 150%, and an asset sold for $2.5 million that was previously valued at $14.9 million [3]. - It was alleged that Marex concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund, misclassifying structured note issuance as income to inflate cash flow [3]. Group 2: Market Reaction - Following the publication of the report, Marex's stock price dropped by $2.33, or 6.2%, closing at $35.31 per share on August 5, 2025, with unusually high trading volume [4]. Group 3: Lawsuit Details - The class action complaint claims that Marex's management made materially false statements and failed to disclose adverse facts about the company's financial health, including inconsistencies in financial statements and reliance on misleading positive statements [5]. - Specific allegations include the sale of over-the-counter financial instruments to itself and the unreliability of Marex's financial statements due to discrepancies in intercompany transactions [5].

NEW YORK--(BUSINESS WIRE)---- $MRX #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marex Group plc ("Marex†or the "Company†) (NASDAQ: MRX) and reminds investors of the December 8, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm ha ...

Core Points - Holzer & Holzer, LLC has filed a shareholder class action lawsuit against Marex, Inc. alleging undisclosed financial practices [1] - The lawsuit claims Marex sold over-the-counter financial instruments to itself and had inconsistencies in financial statements [1] - It is asserted that Marex's financial statements could not be relied upon, leading to misleading positive statements about the company's operations [1] Legal Context - Shareholders who purchased Marex shares between May 16, 2024, and August 5, 2025, and suffered losses are encouraged to seek legal advice [2] - The deadline to apply for lead plaintiff status in the lawsuit is December 8, 2025 [3] - Holzer & Holzer, LLC is recognized for its representation of shareholders and has recovered significant amounts for victims of corporate misconduct [3]

Core Viewpoint - A class action lawsuit has been filed against Marex Group PLC, alleging significant accounting irregularities and misleading disclosures that have impacted investors during the specified Class Period from May 16, 2024, to August 5, 2025 [1][5]. Summary by Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Southern District of New York, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1]. - Investors have a 60-day window from the notice date to move the Court to serve as lead plaintiff in this action [2][6]. Allegations Against Marex - A report by NINGI Research on August 5, 2025, accused Marex of engaging in a multi-year accounting scheme involving off-balance-sheet entities and fictitious transactions to conceal losses and inflate profits [3]. - Specific allegations include a $17 million receivable created without basis, a subsidiary's profit inflated by 150%, and a $14.9 million asset sold for only $2.5 million shortly after, with no loss reported [3]. - The report also claimed Marex concealed nearly $1 billion in off-balance-sheet derivatives exposure through a Luxembourg fund, misclassifying structured note issuance as income [3]. Market Reaction - Following the allegations, Marex's stock price dropped by $2.33, or 6.2%, closing at $35.31 per share on August 5, 2025, with unusually high trading volume [4]. Misleading Statements - The complaint alleges that Marex made materially false and misleading statements throughout the Class Period, failing to disclose critical adverse facts about its business and financial health [5]. - Specific failures included undisclosed over-the-counter financial instruments sold to itself and inconsistencies in financial statements among subsidiaries [5].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who sold short Marex Group PLC securities, alleging that the company misled investors regarding its revenue projections and inflated its financial metrics through improper accounting practices [1][2]. Group 1: Allegations Against Marex Group PLC - The lawsuit claims that Marex Group PLC failed to disclose that it improperly inflated its cash flow, revenues, assets, and profits in its Market Making segment through off-book intercompany transactions [2]. - As a result of these alleged misrepresentations, class members have reportedly suffered significant losses and damages [2]. Group 2: Class Action Participation - Investors who sold short Marex Group PLC securities between August 14, 2024, and August 5, 2025, may be eligible to participate in the class action [1]. - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by December 8, 2025 [3]. - Participation in the case is not required to be eligible for recovery; investors can remain absent class members if they choose not to take action [3]. Group 3: About Robbins LLP - Robbins LLP is recognized as a leader in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [4].

Core Viewpoint - Scott+Scott Attorneys at Law LLP has filed a securities class action lawsuit against Marex Group plc and certain of its directors and officers, alleging misleading statements and omissions regarding the company's financial condition and business practices during the Class Period [1][4]. Company Overview - Marex Group plc is a diversified global financial services platform based in the United Kingdom, operating five reporting segments: Clearing, Agency and Execution, Market Making, Hedging and Investment Solutions, and Corporate [3]. Allegations - The Class Action claims that Marex improperly inflated its cash flow and the revenues, assets, and profits of its Market Making segment through off-book intercompany transactions, misleading investors about its financial health [4]. - Defendants' misleading statements led to short selling of Marex securities at artificially inflated prices, resulting in damages when the truth was revealed [5].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Marex Group PLC for possible violations of federal securities laws and unlawful business practices, encouraging affected investors to reach out for legal options [1][2]. Investigation Details - The investigation is prompted by a report from NINGI Research, which alleges that Marex has been involved in a multi-year accounting scheme, utilizing opaque off-balance-sheet entities and misleading disclosures to hide significant losses and inflate profits [6]. - The report claims that Marex's financial statements are unreliable, describing the company's financial structure as a "financial house of cards" [6]. Stock Impact - Following the release of the NINGI Research report, Marex's stock price dropped by $2.33, or 6.19%, closing at $35.31 per share on August 5, 2025 [6].

Core Insights - Marex Group (NASDAQ: MRX) experienced a significant stock market performance, with shares rising nearly 12% following the release of preliminary third-quarter figures, outperforming the S&P 500's 0.6% increase [1] Financial Performance - For the third quarter ending September 30, Marex estimated revenue between $475 million and $485 million, indicating substantial growth from $391 million in the same quarter of 2024 [2] - The company anticipates GAAP net profit to be between $70 million and $73 million, compared to $58 million in the third quarter of 2024. Non-GAAP adjusted profit per share is projected at $0.92 to $0.97, up from $0.76 a year ago [3] Management Commentary - CEO Ian Lowitt stated that the recent performance reflects the strength and resilience of the company's franchise, designed to grow across various market environments [4] Upcoming Events - Official audited results are set to be published on November 6, accompanied by a management conference call, which will provide further insights into the quarter's performance [4]